



Stakeholder Engagement In A Comparative Effectiveness/Implementation Study To Prevent CA-MRSA Infection Recurrence: CA-MRSA Project (CAMP2)

Journal:	<i>Progress in Community Health Partnerships: Research, Education, and Action</i>
Manuscript ID	Draft
Manuscript Type:	Work in Progress and Lessons Learned
Date Submitted by the Author:	n/a
Complete List of Authors:	D'Orazio, Brianna; Clinical Directors Network Ramachandran, Jessica; Clinical Directors Network Inc; Metropolitan Hospital Center Khalida, Chamanara; Clinical Directors Network Gonzalez, Johana; Clinical Directors Network Kost, Rhonda; The Rockefeller University Center for Clinical and Translational Science (CCTS), Center for Clinical and Translational Science Vasquez, Kimberly; The Rockefeller University Center for Clinical and Translational Science (CCTS), Center for Clinical and Translational Science Evering, Teresa; The Rockefeller University Center for Clinical and Translational Science (CCTS), Center for Clinical and Translational Science Hassen, Getaw; Metropolitan Hospital Center Hammock, Regina; Coney Island Hospital Nguyen, Rosalee; Coney Island Hospital Davis, Ronette; Coney Island Hospital Millan, Keenan; NYU Lutheran Medical Center Parola, Claude; Urban Health Plan Inc Coller, Barry; The Rockefeller University Center for Clinical and Translational Science (CCTS), Center for Clinical and Translational Science Tobin, Jonathan; Clinical Directors Network, Inc. (CDN); The Rockefeller University Center for Clinical and Translational Science (CCTS), Center for Clinical and Translational Science
Keywords:	Methicillin-Resistant Staphylococcus aureus (MRSA), Antibiotic-resistance, Skin and Soft Tissue Infection (SSTI), Colonization, Community Health Workers/Promotoras, Patient Stakeholder Advisory Committee, Community-based Participatory Research (CBPR), Randomized Clinical Trial (RCT), Practice-based Research Network (PBRN), Comparative Effectiveness Research (CER)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3 STAKEHOLDER ENGAGEMENT IN A COMPARATIVE
4 EFFECTIVENESS/IMPLEMENTATION STUDY TO PREVENT CA-MRSA INFECTION
5 RECURRENCE:
6 CA-MRSA Project (CAMP2)
7
8
9

10 AUTHORS AND AFFILIATIONS

11
12 Brianna D’Orazio, MPH^{1*}
13 Jessica Ramachandran, MD^{1,2*}
14 Chamanara Khalida, MD, MPH¹
15 Johana Gonzalez, MD¹
16 Rhonda G. Kost, MD³
17 Kimberly S. Vasquez, MPH³
18 Teresa H. Evering, MD MS³
19 Getaw Worku Hassen, MD²
20 Regina Hammock, DO⁴
21 Rosalee Nguyen, DO⁴
22 Ronette Davis⁴⁺
23 Keenan Millan⁵⁺
24 Claude Parola, MD⁶
25 Barry S. Collier, MD³
26 Jonathan N. Tobin, PhD^{1,3}
27
28
29
30

31
32 ¹Clinical Directors Network (CDN) (New York, NY)

33
34 ²Metropolitan Hospital/New York City Health + Hospitals (New York, NY)

35
36 ³The Rockefeller University Center for Clinical and Translational Science (New York, NY)

37
38 ⁴Coney Island Hospital/New York City Health + Hospitals (Brooklyn, NY)

39
40 ⁵NYU Lutheran Family Health Center and Medical Center (NYU Langone at Brooklyn)
41 (Brooklyn, NY)

42
43 ⁶Urban Health Plan (Bronx, NY)

44
45 + Patient stakeholders

46
47 *These authors contributed equally to this work.

48
49 Funding: PCORI #CER-1402-10800

50
51 ClinicalTrials.gov Identifier: NCT02566928

52 The statements presented in this article are solely the responsibility of the authors and do not
53 necessarily represent the views of the National Institutes of Health, the Patient-Centered
54 Outcomes Research Institute® (PCORI®), its Board of Governors or Methodology Committee.
55
56
57
58
59
60

CORRESPONDING AUTHOR: Jonathan N. Tobin, Ph.D., Clinical Directors Network (CDN) and The Rockefeller University Center for Clinical and Translational Science. JNTobin@CDNetwork.org

WORD COUNT FOR ABSTRACT: 150 words

WORD COUNT FOR PAPER BODY (excluding abstract, acknowledgements, references, tables and figures): (maximum 3000 words): 2676 words

KEY WORDS: Methicillin-Resistant *Staphylococcus aureus* (MRSA); Antibiotic-resistance; Skin and Soft Tissue Infection (SSTI); Colonization; Community Health Workers/Promotoras; Patient Stakeholder Advisory Committee; Community-based Participatory Research (CBPR); Randomized Clinical Trial (RCT)

RUNNING HEAD: Stakeholder Engagement Community-Associated MRSA

ABSTRACT

Background

Methicillin-Resistant (MRSA) or Methicillin-Sensitive (MSSA) *Staphylococcus aureus* skin and soft tissue infections (SSTIs) pose serious clinical and public health challenges. Few protocols exist for outpatient education, decolonization and decontamination.

Objectives

This trial implemented infection prevention protocols in homes via Community Health Workers/promotoras.

Methods

We engaged clinicians, patients, clinical and laboratory researchers, New-York-based Federally Qualified Health Centers and community hospital Emergency Departments. The Clinician and Patient Stakeholder Advisory Committee (CPSAC) convened in-person and remotely for shared decision-making and trial oversight.

Results

The trial consented 186 and randomized 119 participants with SSTIs with MRSA (n=59) or MSSA (n=59), completed home visits, obtained surveillance cultures from index patients and household members and sampled household environmental surfaces at baseline and three months.

Lessons Learned

The retention of the CPSAC during the trial demonstrated high levels of engagement.

Conclusions

CPSAC was highly effective throughout design and execution by troubleshooting recruitment and home visit challenges.

BACKGROUND

Methicillin-Resistant *Staphylococcus aureus* (MRSA) is a multi-drug resistant infection that poses serious clinical and public health challenges. As a main cause of treatment-resistant skin and soft tissue infections (SSTIs)^{1,2}, MRSA carries significant morbidity and mortality, and impacts patients, families, caregivers, and health-care institutions^{3,4}. While effective protocols for hospital-acquired/healthcare-associated MRSA (HA-MRSA) exist⁵, few have been adapted for use in community settings for community-associated MRSA (CA-MRSA⁶⁻¹¹) which affects otherwise healthy, younger individuals without exposure to healthcare risk factors or contacts¹². Little research has examined the feasibility and effectiveness of implementing evidence-based infection prevention interventions in primary care settings¹³ and no studies have employed Community Health Workers (CHWs) or “Promotoras” to provide home-based education and training in decolonization and decontamination. The CA-MRSA Project 2 (CAMP2) was designed to test the effectiveness and implementation of an evidence-based intervention tested and shown to be effective in the hospital intensive care unit (ICU) setting.⁵

One of the most notable features of this patient-centered outcomes research study was the engagement of multiple academic and community-based stakeholders in critical phases of the trial. The stakeholder partnership was built upon a long-term, multi-year, highly-engaged community-academic research and learning collaborative that included practicing clinicians, patients, clinical researchers, laboratory researchers, several New-York-based Federally Qualified Health Centers (FQHCs), and several Community Hospital Emergency Departments (EDs).¹⁴ In this article, we describe some of the logistical and procedural aspects of the community-based participatory research (CBPR) and practice-based research network (PBRN) methodologies that were used in

1
2
3 the design and conduct of this trial and further highlight the ways in which stakeholders contributed
4
5 to the CAMP2 trial.
6
7
8
9

10 **METHODS**

11
12 The CAMP2 study was conceptualized by a group of stakeholders during a prior
13 observational epidemiologic study, the CA-MRSA Project 1 (CAMP1), which examined the
14 correlates, treatments, and outcomes for patients with SSTIs presenting for treatment with
15 microbiologically confirmed *S. aureus* infections (either MRSA or MSSA).
16
17
18
19
20

21
22 CAMP2 was the next logical step in this CBPR partnership, where we endeavored to
23 intervene upon patient-centered features that we observed in the CAMP1 study. The CAMP2 trial
24 tested a community-based intervention to enhance outpatient treatment for CA-MRSA. This
25 comparative effectiveness/patient centered outcomes research trial recruited participants at three
26 FQHCs and three EDs in New-York City. Eligible participants: (1) were between 7-70 years; (2)
27 were fluent in English or Spanish; (3) planned to continue to receive care in the FQHC or ED
28 during the next year; (4) presented with signs and symptoms of a SSTI; (5) had a laboratory-
29 confirmed baseline wound culture positive for MRSA or MSSA (patients who met inclusion
30 criteria but whose SSTI culture was positive for *S. aureus* without antibiotic resistance, or MSSA+,
31 were also enrolled because their risk for recurrence is similar to that of patients with MRSA+
32 wound cultures); (6) were willing/able to provide informed consent; and (7) willing to participate
33 in the baseline and follow-up home visits.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 Recruitment, informed consent, and baseline clinical assessment were conducted by trained
50 CHW/Promotoras, who worked in collaboration with FQHC/ED clinicians and office staff. Data
51 collected included clinical laboratory results from microbiological cultures taken from the
52
53
54
55
56
57
58
59
60

DO NOT CITE OR REPRODUCE WITHOUT PRIOR AUTHORIZATION

1
2
3 participants' wound(s), as well as surveillance cultures from the nares, axilla, and groin. Additional
4
5 data collected included a detailed dermatologic assessment, clinical and demographic data
6
7 extracted from the electronic health records (EHRs), molecular epidemiologic characterizations of
8
9 the wound, surveillance and household specimens, environmental assessments obtained by
10
11 CHW/promotoras during baseline and follow-up home visits, as well as responses to patient-
12
13 reported surveys (pain, depression, quality of life, satisfaction with care).
14
15

16
17 All participants received clinician-directed standard-of-care treatment, including incision
18
19 and drainage (I&D) and/or oral antibiotics. Participants were assessed at baseline and then
20
21 randomized to experimental or control condition.
22
23

24 Two interventions were compared: (1) CDC-Guidelines directed care (i.e., incision and
25
26 drainage (I&D) and antibiogram-selected oral antibiotics^{15,16} and an educational pamphlet; (Usual
27
28 Care) versus (2) CDC Guidelines-directed care combined with universal household decolonization
29
30 and environmental decontamination interventions based on the REDUCE MRSA Trial^{15,15,16},
31
32 provided in the home by CHW/Promotoras (Experimental Group). Specifically, we evaluated the
33
34 comparative effectiveness on SSTI recurrence rates (primary outcome) and secondary patient-
35
36 centered outcomes (pain, depression, quality of life, care satisfaction) using a two-arm 1:1
37
38 randomized controlled trial. With the multiplicity of stakeholders' perspectives in mind¹⁷, we
39
40 arrived at the shared research priority of preventing infection recurrence and household
41
42 transmission. The experimental intervention was designed to enhance participants' MRSA
43
44 knowledge and encourage self-efficacy, active self-management and preventive health behaviors¹⁸
45
46 (Table 1). Participants had follow-up home visits at three months and EHRs were reviewed for
47
48 SSTI recurrence over six months following the index SSTI treatment.
49
50
51
52
53
54
55
56
57
58
59
60

CBPR Methodology

Clinician and Patient Stakeholder Advisory Committee (CPSAC) Composition and Procedures

The Clinician and Patient Stakeholder Advisory Committee (CPSAC) brought together patient stakeholders (i.e., members of the community who were not enrolled in this trial), staff from six New York City area FQHCs and EDs, staff from Clinical Directors Network (CDN, www.CDNetwork.org), a primary care practice-based research network (PBRN) and AHRQ-designated Center of Excellence for Practice-based Research and Learning (#1 P30-HS-021667), as well as academicians and clinicians from the NIH/NCATS-funded Clinical and Translational Science Award (CTSA) (#8 UL-1 TR-000043) at the Center for Clinical and Translational Science at The Rockefeller University, and scientists from the Laboratory of Microbiology and Infectious Diseases at The Rockefeller University (see Table 2). Patient stakeholders were recruited from among previous CAMP1 participants, which included participants in the observational study, focus groups and Research Town Hall meetings. In addition, the CPSAC included the designated patient representative from an FQHC, and one patient representative from each ED (n=3). CDN recruited one additional community representative to serve on the CPSAC, a local businessman and barbershop owner from previously conducted MRSA and Hepatitis C CTSA-funded pilot studies that developed and tested MRSA and Hepatitis C education with staff working at NYC barbershops¹⁹.

The CPSAC met in person or via teleconference, as determined by the participants, with logistical and financial support provided by CDN. Meetings were held every 1-2 months, either in-person at The Rockefeller University (2-3 hours) or by web/teleconference (1-1.5 hours). A total of 25 CPSAC meetings were held throughout the course of the project. CPSAC roles are summarized in Table 3. During the CPSAC meetings, the team discussed study conduct and

DO NOT CITE OR REPRODUCE WITHOUT PRIOR AUTHORIZATION

1
2
3 progress, identified barriers and opportunities, recommended strategies to increase recruitment,
4 engagement, and retention of study participants, and developed opportunities for dissemination.
5
6

7
8 To engage stakeholders outside CPSAC meetings, we also initiated regular communiques
9 and encouraged stakeholders to provide ongoing input through emails and phone calls. Thus, there
10 were numerous email threads that reflected shared decision-making. This active engagement of
11 stakeholders fostered equitable collaboration by focusing on ongoing and multi-level
12 communications and ensured transparency at each step. Through all stages of the project, our
13 stakeholders shared their perspectives, preferences, and priorities.
14
15
16
17
18
19
20

21 Academic, clinician, and CHW stakeholders participated in robust discussions as to
22 whether to conduct *S. aureus* surveillance among CHWs, based on a review of the literature and
23 the occupational safety perspective from the CHW standpoint. Stakeholder discussions with
24 experts in infectious diseases and infection control resulted in the decision not to conduct routine
25 CHW surveillance, given that in settings with higher rates of MRSA exposure, such as the hospital
26 ICU, colonization in health care workers is low²⁰⁻²², and persistent carriage is rare^{23,24}. CHW
27 training included guidelines for infection prevention, similar to precautions taken by healthcare
28 workers in settings with higher infection exposure and transmission risk.
29
30
31
32
33
34
35
36
37
38
39
40
41

42 **LESSONS LEARNED**

43 Value Added by Patient and Community Partners

44
45
46
47 The CPSAC and CHWs/promotoras routinely met to provide input and guidance on all
48 aspects of the project. Working together, academic, clinician, CHW, and patient stakeholders made
49 recommendations for various aspects of the trial, including but not limited to: (a) designing the
50 home intervention, (b) selecting the primary outcomes and their measurement, (c) ensuring that
51
52
53
54
55
56
57
58
59
60

1
2
3 patient-centered outcomes were meaningful, without being burdensome to study participants, (d)
4
5 improving patient identification/recruitment, (e) obtaining informed consent, (f) intervention
6
7 delivery (g) methods to improve the scheduling and completion of home visits, (g) retention goals,
8
9
10 (h) planning dissemination activities, (i) the protocol's burden on participants, and (j) feedback on
11
12 protocol changes.

13
14
15 In the CAMP1 study, study participants, the research team, and clinicians identified
16
17 important topics that we chose to further explore in CAMP2¹⁴. For example, stakeholders stressed
18
19 the importance of patient education and support designed to inform participants of how the index
20
21 patient and their household members could work together to implement low-cost hygienic and
22
23 environmental steps to reduce the index patient's risk of recurrent infections and prevent
24
25 transmission to household members.
26
27

28
29 During the design phase of CAMP2, the stakeholders voiced strong concerns that while
30
31 patients with MRSA received excellent decolonization and decontamination practices in-hospital,
32
33 their needs were largely unaddressed once they left the hospital setting. At a series of community
34
35 engagement meetings, stakeholders articulated their perspectives on developing a project to
36
37 address CA-MRSA in the household environment, in response to a case presentation by an FQHC
38
39 clinician of a CAMP1 participant with multiple recurrences.²⁵ The participant was treated with
40
41 I&D and antibiotics, but an SSTI recurred, and MRSA was now present in her sister who was
42
43 visiting her apartment. This case study was subsequently published by one of the FQHC clinicians
44
45 as the lead author²⁵.
46
47
48

49
50 CAMP2 stakeholders and staff also discussed issues related to the conduct of home visits
51
52 during early CPSAC meetings. Meeting attendees voiced concerns that participants might hesitate
53
54 to invite strangers into their homes, or participants might cite “lack of trust” as a reason for failing
55
56
57
58
59
60

1
2
3 to enroll or withdrawing from the trial. Another issue included participants' fears of potential
4 shaming and stigmatization about their home being "dirty" or "contaminated". These concerns
5 were addressed through the utilization of CHWs/Promotoras to implement the home visits, as well
6 as in engaging the Community Health Worker Network of New York City to train study CHWs.
7
8
9

10
11 Stakeholders also defined the optimal process by which the project team could reach
12 community audiences, providing input on discussions of cultural sensitivity, patient autonomy,
13 shaming and stigmatization related to potential home contamination, and community health
14 priorities. To address these concerns, attendees suggested having two CHWs/promotoras attend
15 each home visit, instituting a warm hand off between clinicians and study staff, employing
16 CHWs/promotoras who were trusted members of the community, and by explicitly addressing
17 shaming and stigmatization in CHW/Promotora training sessions. The CPSAC also suggested
18 additional content for training CHWs/promotoras, outlining the manner by which
19 CHWs/promotoras should rehearse and demonstrate their competence. Academic, clinician,
20 CHW, and patient stakeholders participated in discussions about improving patient identification
21 and consent, methods to improve the scheduling and completion of home visits, and ways to
22 improve the consent rate of household members.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 Where appropriate, stakeholder subgroups were asked to provide input on issues germane
41 to their expertise. CHW stakeholders tested the data collection application and refined informed
42 consent language and assessment procedures to address language, literacy and cultural sensitivity.
43 Community clinician stakeholders participated in refining and finalizing the study protocol,
44 adapting and expanding the clinical workflow, and identifying patient and clinician engagement
45 strategies. Academic stakeholders shaped discussions about patient consent and human subjects
46 protection, the quality and acceptability of educational materials, the laboratory measures, and the
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 patient-centered and self-reported outcomes assessment battery. They also provided input based
4
5 on recently published literature on CA-MRSA and the home environment/microbiome, and guided
6
7 the discussion of methods to measure intervention fidelity. Academic stakeholders also conducted
8
9 ongoing discussions on building capacity for patient stakeholders to have an influence on the
10
11 health of their communities. Both clinician and academic stakeholders were engaged in the
12
13 development of the study-specific CHW training protocol (see Appendix D), which was
14
15 implemented by an established, well-recognized CHW training organization, Community Health
16
17 Worker Network of New York City (www.CHWNetwork.org). They were also involved in
18
19 planning dissemination activities. Patient stakeholders were engaged in discussions about
20
21 increasing the scope of dissemination venues in the community. They were additionally asked for
22
23 feedback regarding protocol changes (e.g., removal of oropharyngeal surveillance swabs), as well
24
25 as the acceptability of dissemination of information only (but not intervention kits), to usual care
26
27 participants at the end of the study.
28
29
30
31
32

33 This active engagement of stakeholders fostered equitable collaboration through shared
34
35 decision-making by focusing on ongoing and multi-level communications and ensuring
36
37 transparency at each step. Our stakeholders shared their perspectives, preferences and priorities at
38
39 all stages of the project. For example, in problem-solving recruitment/retention challenges,
40
41 stakeholders suggested a more personalized exchange among the site clinicians, study recruitment
42
43 staff and CHW/Promotoras. As such, we instituted a “warm handoff”, whereby the site clinician
44
45 directly introduced the patient to the study recruiter and CHW/promotora and invited the patients
46
47 to participate in the study²⁶. In theory, when a patient has an established relationship with the
48
49 clinician, a warm hand off by the clinician is thought to increase the likelihood that the patient will
50
51 agree to participate in the study (“trust-by-proxy”). This procedure includes the patient as an active
52
53
54
55
56
57
58
59
60

1
2
3 team member and engages the patient in the shared decision-making process. We found this added
4
5 step to improve retention.
6

7
8 In addition, we were particularly eager to understand why one-third of the participants who
9
10 consented to home visits withdrew from the study before they were informed about their
11
12 randomized treatment assignment, and therefore never received the intervention. Home visit
13
14 implementation presented a major challenge due to participants either being unreachable following
15
16 their baseline visit to the FQHC or ED for treatment of their SSTIs, or they were unwilling or
17
18 unable to participate due to subsequent lack of agreement by other members in the household. The
19
20 perceived and actual intrusiveness of home visits proved difficult to overcome. When we shared
21
22 this difficulty of retention of participants who were recruited in clinical settings but refused to
23
24 participate once the project team contacted them at home, the CPSAC was instrumental in
25
26 performing a “leaky pipe analysis” (see Table 4). This analysis examined the flow of patients over
27
28 the study's lifecycle, from presenting for care and informed consent to baseline home visit
29
30 completion, and explored the points at which participants withdrew from the study. We undertook
31
32 this analysis to improve our retention rates and to guide other community-based research projects
33
34 with similar research designs. Based on stakeholder guidance we changed several procedures of
35
36 the study. For example, we began making appointments at the FQHC or ED with each patient who
37
38 provided informed consent (prior to laboratory confirmation), and subsequently cancelled
39
40 appointments if the microbiological assessment showed that patients infection was not due to
41
42 MRSA.
43
44
45
46
47
48

49 Continued Engagement of Patient and Community Partners

50
51 Stakeholders were highly engaged as evidenced by their enthusiasm and follow-through
52
53 over the study period. We observed that the retention during the project of the CPSAC community
54
55
56
57
58
59
60

1
2
3 and patient stakeholders was excellent, indicating an extremely high level of stakeholder
4 engagement. Among the community partners, 100% remained with the project throughout the
5 entire study and continue to collaborate as advisors in new patient-centered outcomes research
6 studies (See Table 3). The involvement, input and continued engagement of stakeholders represent
7 an important and integral feature of the design, conduct, and dissemination of CAMP2.
8
9
10
11
12
13

14 15 16 17 **CONCLUSIONS**

18
19 CAMP2 aimed to intervene at multiple levels in the patient's ecosystem, including the
20 systems, patient, pathogen, and environmental factors associated with MRSA SSTI recurrence and
21 household transmission. CAMP2 was designed based on the input of a diverse stakeholder group
22 of practicing clinicians, patients, clinical researchers, laboratory researchers, and
23 CHWs/promotoras. Convening the CPSAC for regular meetings gained input and guidance across
24 all aspects of the project and encouraged sustained involvement of stakeholders in decision-
25 making processes.
26
27
28
29
30
31
32
33
34

35 One limitation of the process evaluation of the CPSAC was the lack of a standardized tool
36 to measure engagement and satisfaction. An engagement survey, delivered at regular intervals,
37 could have helped quantify stakeholder satisfaction. Future analyses will examine the growth over
38 time using network and sociometric methods.
39
40
41
42
43

44 The members of the CPSAC were instrumental from design through implementation of
45 this comparative effectiveness/patient-centered outcomes research study. They contributed to
46 hypothesis development and study design, as well as identified potential areas of concern during
47 the conduct of the study, represented the patient and community-clinician points of view, and
48 identified remedies for various study challenges (e.g., recruitment and retention). CPSAC
49
50
51
52
53
54
55
56
57
58
59
60

DO NOT CITE OR REPRODUCE WITHOUT PRIOR AUTHORIZATION

1
2
3 members remained highly engaged throughout the project and were effective at strengthening the
4
5 project as a whole.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

REFERENCES

1. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant *S. aureus* infections among patients in the emergency department. *N Engl J Med*. 2006;355(7):666-674.
2. Farr AM, Aden B, Weiss D, Nash D, Marx MA. Trends in hospitalization for community-associated methicillin-resistant *Staphylococcus aureus* in New York City, 1997-2006: data from New York State's Statewide Planning and Research Cooperative System. *Infect Control Hosp Epidemiol*. 2012;33(7):725-731.
3. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant *Staphylococcus aureus* infections in the United States. *Jama*. 2007;298(15):1763-1771.
4. Centers for Disease Control and Prevention. Methicillin-resistant *Staphylococcus aureus* (MRSA) infection in healthcare settings. <http://www.cdc.gov/HAI/organisms/mrsa-infection.html>. Published 2012. Accessed February 2, 2019.
5. Huang SS, Septimus E, Kleinman K, et al. Targeted versus universal decolonization to prevent ICU infection. *N Engl J Med*. 2013;368(24):2255-2265.
6. Tenover FC, Goering RV. Methicillin-resistant *Staphylococcus aureus* strain USA300: origin and epidemiology. *J Antimicrob Chemother*. 2009;64(3):441-446.
7. Cluzet VC, Gerber JS, Metlay JP, et al. The Effect of Total Household Decolonization on Clearance of Colonization With Methicillin-Resistant *Staphylococcus aureus*. *Infect Control Hosp Epidemiol*. 2016;37(10):1226-1233.
8. Huang SS, Septimus E, Kleinman K, et al. Chlorhexidine versus routine bathing to prevent multidrug-resistant organisms and all-cause bloodstream infections in general medical and surgical units (ABATE Infection trial): a cluster-randomised trial. *Lancet (London, England)*. 2019;393(10177):1205-1215.
9. Papastefan ST, Buonpane C, Ares G, Benyamen B, Helenowski I, Hunter CJ. Impact of decolonization protocols and recurrence in pediatric MRSA skin and soft-tissue infections. *J Surg Res*. 2019;242:70-77.
10. Fritz SA, Hogan PG, Hayek G, et al. Household versus individual approaches to eradication of community-associated *Staphylococcus aureus* in children: a randomized trial. *Clin Infect Dis*. 2012;54(6):743-751.
11. Ellis MW, Griffith ME, Dooley DP, et al. Targeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin-resistant *Staphylococcus aureus* strains in soldiers: a cluster randomized controlled trial. *Antimicrobial agents and chemotherapy*. 2007;51(10):3591-3598.
12. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF. Community-associated methicillin-resistant *Staphylococcus aureus*. *Lancet*. 2010;375(9725):1557-1568.
13. Fritz SA, Camins BC, Eisenstein KA, et al. Effectiveness of measures to eradicate *Staphylococcus aureus* carriage in patients with community-associated skin and soft-tissue infections: a randomized trial. *Infect Control Hosp Epidemiol*. 2011;32(9):872-880.
14. Kost RG, Leinberger-Jabari A, Evering TH, et al. Helping basic scientists engage with community partners to enrich and accelerate translational research. *Academic medicine : journal of the Association of American Medical Colleges*. 2017;92(3):374-379.
15. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2014;59(2):e10-52.

16. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Disease Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis*. 2011;52(3):e18-55.
17. Patient-Centered Outcomes Research Institute. Patient-Centered Outcomes Research. <https://www.pcori.org/research-results/patient-centered-outcomes-research>. Published 2013. Accessed 2 February 2019.
18. Pardos de la Gandara M, Raygoza Garay JA, Mwangi M, et al. Molecular types of methicillin-resistant *Staphylococcus aureus* and methicillin-sensitive *Staphylococcus aureus* strains causing skin and soft tissue infections and nasal colonization, identified in community health centers in New York City. *J Clin Microbiol*. 2015;53(8):2648-2658.
19. Leinberger-Jabari A, Kost RG, D'Orazio B, et al. From the bench to the barbershop: community engagement to raise awareness about community-acquired methicillin-resistant *Staphylococcus aureus* and Hepatitis C virus infection. *Progress in community health partnerships : research, education, and action*. 2016;10(3):413-423.
20. Dulon M, Peters C, Schablon A, Nienhaus A. MRSA carriage among healthcare workers in non-outbreak settings in Europe and the United States: a systematic review. *BMC infectious diseases*. 2014;14:363.
21. Johnston CP, Stokes AK, Ross T, et al. *Staphylococcus aureus* colonization among healthcare workers at a tertiary care hospital. *Infect Control Hosp Epidemiol*. 2007;28(12):1404-1407.
22. Price JR, Cole K, Bexley A, et al. Transmission of *Staphylococcus aureus* between health-care workers, the environment, and patients in an intensive care unit: a longitudinal cohort study based on whole-genome sequencing. *Lancet Infect Dis*. 2017;17(2):207-214.
23. Cookson B, Peters B, Webster M, Phillips I, Rahman M, Noble W. Staff carriage of epidemic methicillin-resistant *Staphylococcus aureus*. *J Clin Microbiol*. 1989;27(7):1471-1476.
24. Siegel JD, Rhinehart E, Jackson M, Chiarello L, Healthcare Infection Control Practices Advisory C. Management of multidrug-resistant organisms in health care settings, 2006. *Am J Infect Control*. 2007;35(10 Suppl 2):S165-193.
25. Balachandra S, Pardos de la Gandara M, Salvato S, et al. Recurrent furunculosis caused by a community-acquired *Staphylococcus aureus* strain belonging to the USA300 clone. *Microb Drug Resist*. 2015;21(2):237-243.
26. Agency for Healthcare Research and Quality. Warm handoff: intervention. U.S. Department of Health and Human Services. <https://www.ahrq.gov/professionals/quality-patient-safety/patient-family-engagement/pfepprimarycare/interventions/warmhandoff.html>. Published 2017. Accessed January 15, 2017.

Table 1. PCORI Patient-Centered Questions Addressed by CAMP2 Trial

PCORI Patient-Centered Questions examined during CAMP1 ¹⁷	CAMP1 Stakeholder Feedback Addressed in CAMP2: Patient-Centered Features Incorporated into the CAMP2 Design
1) <u><i>“Given my personal characteristics, conditions, and preferences, what should I expect will happen to me?”</i></u>	78% of CAMP1 patients rated reducing the spread of MRSA in their household as “very important” to them. Moreover, 84% rated preventing their MRSA infection from coming back as “very important”. One of the goals of this project was to reduce future recurrence and uncertainty. Patient education and self-efficacy were crucial to the implementation of this intervention. CHW/Promotoras collaborated in developing the home visit scripts and protocol to address the cultural, socioeconomic, and medical needs of patients.
2) <u><i>“What are my options and what are the potential benefits and harms of those options?”</i></u>	The CAMP2 study compared the effectiveness of two interventions to prevent MRSA recurrence . If effective when implemented in the community-based settings, the intervention could help reduce the spread of MRSA infection and reduce future morbidity and suffering. Given the patients who received care in the health systems settings that provide care to an urban, multi-ethnic low income population, many of whom have been disenfranchised by the health care system, all protocols were highly sensitive to participants’ autonomy and their role as the ultimate decision-maker.
3) <u><i>“What can I do to improve the outcomes that are most important to me?”</i></u>	Qualitative results demonstrated that patients were most concerned about recurrence, pain, and ability to perform functions . CAMP2 intervention aims to empower patients to play a more active role in reducing the burden of recurrent MRSA infections through tools and methods to decolonize themselves and household members and to disinfect their households ¹⁸ .
4) <u><i>“How can clinicians and the care delivery systems they work in help me make the best decisions about my health and healthcare?”</i></u>	Through close relationships with the communities they serve, clinicians in FQHCs and community hospital emergency departments, worked with study-supported staff, including onsite study recruiters. To minimize impact on practice workflow, research staff were present and obtained informed consent in a collaborative style, to ensure that each participant understood that the project was designed to help them make the best decisions for themselves, and to take active steps to reduce the possibility of infection recurrence and household transmission.

Table 2. Community and Patient Stakeholder Advisory Committee Roles and Composition

Stakeholder Type	Description of Role	# FQHCs	# EDs	TOTAL
Clinicians	<ul style="list-style-type: none"> · Conducted patient screening and recruitment · Obtained informed consent · Assessed dermatological symptoms, collected specimen, treated wounds, among other activities during Baseline Study Visit · Assisted with follow-up of “warm handoff” protocol · Participated in stakeholder meetings 	4	5	9
CHW/ Promotoras	<ul style="list-style-type: none"> · Conducted patient screening and recruitment · Obtained informed consent · Participated in “warm handoff” protocol · Conducted home visits · Conducted telephone assessments · Participated in stakeholder meetings 	2	4	6
Patients/ Community Members	<ul style="list-style-type: none"> · Determined acceptability of education materials and home visit protocol elements · Proposed community-based dissemination opportunities · Reviewed assessment measures and home visit schedule · Participated in stakeholder meetings 	1	4	5
TOTAL		7	13	20

Table 3. Retention/Turnover CAMP2 Research Team

TYPE OF STAKEHOLDER	# Beginning of study	# End of study	% Retention
FQHC/HOSP ED*	23	13	57%
ACADEMIC/MEDICAL CENTER	24	19	79%
PBRN	17	9	53%
PATIENT/ COMMUNITY PARTNER	5	5	100%
PRIVATE/CORPORATE PARTNER	4	2	50%
FUNDER	3	3	100%
TOTAL	76	51	67%

*FQHC/HOSP ED=Federally Qualified Health Center/Hospital Emergency Department

For Peer Review

DO NOT CITE OR REPRODUCE WITHOUT PRIOR AUTHORIZATION

Table 4. “Leaky Pipe” Model for Evaluating Recruitment and Home Visits Completion

CAMP2 "Leaky Pipe" Model for Evaluating Recruitment and Home Visits

Sites	# Screened	# Recruited	A % Recruited of Patients Screened	# Enrolled (MRSA+/MSSA+)	B % S. aureus positive	Baseline Home Visits Scheduled for All Recruited Patients [^]	Baseline Home Visits Scheduled for Confirmed Eligible Patients	C % Scheduled of Positive Patients	Baseline Home Visits Completed	D % Home Visits Completed of # Scheduled	
FQHC A	89	33	37%	17	52%	11	11	65%	10	91%	
FQHC B	4	2	50%	2	100%	2	2	100%	2	100%	
FQHC C	22	18	82%	7	39%	4	4	57%	4	100%	
ED A	238	210	88%	93	44%	57	53	57%	52	98%	
ED B	194	124	64%	54	44%	49	47	87%	44	94%	
ED C	55	34	62%	13	38%	8	8	62%	8	100%	
TOTAL	602	421	70%	186	44%	131	125	67%	120*	96%	
GOAL				278					278		
%MRSA+/MSSA+				44.1%	% of original goal (n=278) who completed baseline home visits (n=120)*				43.2%		

[^]Total, including those scheduled using protocol to schedule at time of consent prior to lab result

*One patient was determined subsequently to have HIA-MRSA and was excluded from the main effects analysis (n=119)

Peer Review

Acknowledgements

Clinical Directors Network, Inc. (CDN) Research Team

Andrea Cassells, MPH; TJ Lin, MPH; Dena Moftah, BA; Anthony Rhabb, MA, Branny F. Tavaréz, MD, Cynthia Mofunanya, MD, Jasbir Singh, MBBS, MPH, Musarrat Rahman, MPH, Raul Silverio, MD, Sisle Heyliger, BA, Tameir Holder, MPH, Umamah Siddiqui, BS, Viktorya Snkhchyan MD, and Lois Lynn, MS.

The Rockefeller University Research Team

Andrea Leinberger-Jabari, MPH, Cameron Coffran, MS, Helen Marie Curry, Maija Neville Williams, MPH, Marilyn Chung, Mina Pastagia, MD, MS, Teresa L. Solomon, JD, Alexander Tomasz, PhD, Hermínia de Lencastre, PhD, and Maria Pardos de la Gandara, MD, PhD.

Federally Qualified Health Centers (FQHCs) and Hospital Emergency Departments (EDs)

Community Health Network: Site Investigator: Satoko Kanahara MD, FAAP and Tyler Evans, MD.

Family Health Centers at NYU Langone: Site Investigator: William Pagano, MD, MPH, Barry Kohn MD, PhD, Isaac Dapkins, MD; Site Staff: Paula Clemons, PA; Viral Patel, MD and Jason Hyde, LMSW, MEd. Patient Stakeholder: Maria Ferrer.

Open Door Family Health Center: Site Investigator: Daren Wu, MD, Site staff: Asaf Cohen, MD.

Urban Health Plan: Site Investigator: Claude Parola, MD, Tracie Urban, RN, Franco A. Barsanti, PharmD; Site Staff: Ali Saleh, PA, Scott Salvato, PA, Jennifer Concepcion.

NYC Health + Hospitals

Coney Island Hospital ED: Site staff: Candace Gopaul.

Metropolitan Hospital ED: Patient Stakeholder: Van Johnson.

Community Stakeholders:

Rosa Perez, RPh (Cordette Pharmacy)

Dennis Mitchell (Denny Moe Barber Shop)

Data and Safety Monitoring Board (DSMB):

Katherine Freeman, DrPH (DSMB Chair, Extrapolate Statistic LLC, Florida Atlantic University)

Marilyn Gaston, MD (DSMB Member, Assistant Surgeon General & HRSA Associate Administrator for Primary Health Care (ret.))

Maria Ferrer (Patient Representative)

DO NOT CITE OR REPRODUCE WITHOUT PRIOR AUTHORIZATION

1
2
3 **Scientific Consultants/Advisors**

4 Susan Huang, MD, MPH (University of California at Irvine)

5
6 Christopher R. Frei, PharmD, MSc (STARNet/University of Texas Health Science Center at San Antonio)

7
8 Eric Lofgren, PhD (Washington State University)

9
10 Christopher Mason, PhD, Ebbrahim Afshinekoo, BS, Chou Chou, MD (Weill Cornell Medicine)

11
12 Shirshendu Chatterjee, PhD, (The City University of New York (CUNY) School of Public Health)

13
14 Sarah Johnson, MD (NYC Department of Health and Mental Hygiene, Public Health and Preventive
15 Medicine Residency Program & CUNY School of Public Health)

16 Bárbara Milioto, E Denise Digirolomo, Edward Clayton (Genpath/Bioreference Labs)

17
18 Vicky Seyfert-Margolies, PhD, Dana Wershiner, Trang Gisler, MS (MyOwnMed, Inc.)

19
20 Suzanne Lechner, PhD, Sara Vargas, PhD, Suzanne Hower, PhD (Consulting Associates, Inc.)

21
22 **Funding Agency**

23 **Patient Centered Outcomes Research Institute (PCORI):** Anne Trontell, MD, MPH, Donna Gentry,
24 MA and Jess Robb, MPH.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60